{"url_path":"/sec/zeox/10-q/2026/cover-page","section_key":"cover-page","section_title":"Cover Page","topic":"sec","document":{"doc_type":"10-Q","doc_date":"2026-06-15","source_url":"https://www.sec.gov/Archives/edgar/data/1557376/0001829126-26-006486-index.html","accession_number":"0001829126-26-006486","cik":"0001557376","ticker":"ZEOX","issuer_name":"Zeo ScientifiX, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1557376/0001829126-26-006486-index.html","primary_entity_key":"0001557376","primary_entity_name":"Zeo ScientifiX, Inc."},"word_count":1345,"has_tables":true,"body_markdown":"false\n2026\nQ2\n--10-31\n0001557376\n\n0001557376\n\n2025-11-01\n2026-04-30\n\n0001557376\n\n2026-06-12\n\n0001557376\n\n2026-04-30\n\n0001557376\n\n2025-10-31\n\n0001557376\n\nus-gaap:SeriesCPreferredStockMember\n\n2026-04-30\n\n0001557376\n\nus-gaap:SeriesCPreferredStockMember\n\n2025-10-31\n\n0001557376\n\n2026-02-01\n2026-04-30\n\n0001557376\n\n2025-02-01\n2025-04-30\n\n0001557376\n\n2024-11-01\n2025-04-30\n\n0001557376\n\nus-gaap:CommonStockMember\n\n2025-01-31\n\n0001557376\n\nus-gaap:AdditionalPaidInCapitalMember\n\n2025-01-31\n\n0001557376\n\nus-gaap:RetainedEarningsMember\n\n2025-01-31\n\n0001557376\n\n2025-01-31\n\n0001557376\n\nus-gaap:CommonStockMember\n\n2026-01-31\n\n0001557376\n\nus-gaap:AdditionalPaidInCapitalMember\n\n2026-01-31\n\n0001557376\n\nus-gaap:RetainedEarningsMember\n\n2026-01-31\n\n0001557376\n\n2026-01-31\n\n0001557376\n\nus-gaap:CommonStockMember\n\n2024-10-31\n\n0001557376\n\nus-gaap:AdditionalPaidInCapitalMember\n\n2024-10-31\n\n0001557376\n\nus-gaap:RetainedEarningsMember\n\n2024-10-31\n\n0001557376\n\n2024-10-31\n\n0001557376\n\nus-gaap:CommonStockMember\n\n2025-10-31\n\n0001557376\n\nus-gaap:AdditionalPaidInCapitalMember\n\n2025-10-31\n\n0001557376\n\nus-gaap:RetainedEarningsMember\n\n2025-10-31\n\n0001557376\n\nus-gaap:CommonStockMember\n\n2025-02-01\n2025-04-30\n\n0001557376\n\nus-gaap:AdditionalPaidInCapitalMember\n\n2025-02-01\n2025-04-30\n\n0001557376\n\nus-gaap:RetainedEarningsMember\n\n2025-02-01\n2025-04-30\n\n0001557376\n\nus-gaap:CommonStockMember\n\n2026-02-01\n2026-04-30\n\n0001557376\n\nus-gaap:AdditionalPaidInCapitalMember\n\n2026-02-01\n2026-04-30\n\n0001557376\n\nus-gaap:RetainedEarningsMember\n\n2026-02-01\n2026-04-30\n\n0001557376\n\nus-gaap:CommonStockMember\n\n2024-11-01\n2025-04-30\n\n0001557376\n\nus-gaap:AdditionalPaidInCapitalMember\n\n2024-11-01\n2025-04-30\n\n0001557376\n\nus-gaap:RetainedEarningsMember\n\n2024-11-01\n2025-04-30\n\n0001557376\n\nus-gaap:CommonStockMember\n\n2025-11-01\n2026-04-30\n\n0001557376\n\nus-gaap:AdditionalPaidInCapitalMember\n\n2025-11-01\n2026-04-30\n\n0001557376\n\nus-gaap:RetainedEarningsMember\n\n2025-11-01\n2026-04-30\n\n0001557376\n\nus-gaap:CommonStockMember\n\n2025-04-30\n\n0001557376\n\nus-gaap:AdditionalPaidInCapitalMember\n\n2025-04-30\n\n0001557376\n\nus-gaap:RetainedEarningsMember\n\n2025-04-30\n\n0001557376\n\n2025-04-30\n\n0001557376\n\nus-gaap:CommonStockMember\n\n2026-04-30\n\n0001557376\n\nus-gaap:AdditionalPaidInCapitalMember\n\n2026-04-30\n\n0001557376\n\nus-gaap:RetainedEarningsMember\n\n2026-04-30\n\n0001557376\n\nzeox:LargeMedicalPracticeGroupAndDistributorMember\n\n2025-11-01\n2026-04-30\n\n0001557376\n\nus-gaap:SalesRevenueNetMember\nus-gaap:CustomerConcentrationRiskMember\nzeox:LargeMedicalPracticeGroupAndDistributorMember\n\n2025-11-01\n2026-04-30\n\n0001557376\n\nzeox:AnotherLargeMedicalPracticeGroupAndDistributorMember\n\n2025-11-01\n2026-04-30\n\n0001557376\n\nus-gaap:SalesRevenueNetMember\nus-gaap:CustomerConcentrationRiskMember\nzeox:AnotherLargeMedicalPracticeGroupAndDistributorMember\n\n2025-11-01\n2026-04-30\n\n0001557376\n\nzeox:LargeDistributorMember\n\n2024-11-01\n2025-04-30\n\n0001557376\n\nus-gaap:SalesRevenueNetMember\nus-gaap:CustomerConcentrationRiskMember\nzeox:LargeDistributorMember\n\n2024-11-01\n2025-04-30\n\n0001557376\n\nzeox:AnotherLargeDistributorMember\n\n2024-11-01\n2025-04-30\n\n0001557376\n\nus-gaap:SalesRevenueNetMember\nus-gaap:CustomerConcentrationRiskMember\nzeox:AnotherLargeDistributorMember\n\n2024-11-01\n2025-04-30\n\n0001557376\n\nzeox:TwoIndividualMedicalPracticesMember\n\n2024-11-01\n2025-04-30\n\n0001557376\n\nus-gaap:SalesRevenueNetMember\nus-gaap:CustomerConcentrationRiskMember\nzeox:TwoIndividualMedicalPracticesMember\n\n2024-11-01\n2025-04-30\n\n0001557376\n\nzeox:CommonSharesIssuableUponTheExerciseOfOptionsAndWarrantsMember\n\n2025-11-01\n2026-04-30\n\n0001557376\n\nzeox:CommonSharesUnissuedSharesOfRestrictedStockMember\n\n2025-11-01\n2026-04-30\n\n0001557376\n\nus-gaap:ConvertibleDebtSecuritiesMember\n\n2025-11-01\n2026-04-30\n\n0001557376\n\nzeox:CommonSharesIssuableUponTheFuturePaymentsMember\n\n2025-11-01\n2026-04-30\n\n0001557376\n\nzeox:CommonSharesIssuableUponTheExerciseOfOptionsAndWarrantsMember\n\n2024-11-01\n2025-04-30\n\n0001557376\n\nzeox:CommonSharesUnissuedSharesOfRestrictedStockMember\n\n2024-11-01\n2025-04-30\n\n0001557376\n\nus-gaap:ConvertibleDebtSecuritiesMember\n\n2024-11-01\n2025-04-30\n\n0001557376\n\nzeox:FinanceLeaseEquipmentMember\n\n2026-04-30\n\n0001557376\n\nzeox:FinanceLeaseEquipmentMember\n\n2025-10-31\n\n0001557376\n\nzeox:ManufacturingEquipmentMember\n\n2026-04-30\n\n0001557376\n\nzeox:ManufacturingEquipmentMember\n\n2025-10-31\n\n0001557376\n\nzeox:SalesRepresentativeAgreementMember\n\n2026-02-01\n2026-04-30\n\n0001557376\n\nzeox:SalesRepresentativeAgreementMember\n\n2025-11-01\n2026-04-30\n\n0001557376\n\nzeox:SalesRepresentativeAgreementMember\n\n2025-02-01\n2025-04-30\n\n0001557376\n\nzeox:SalesRepresentativeAgreementMember\n\n2024-11-01\n2025-04-30\n\n0001557376\n\nzeox:LeaseAgreementMember\n\n2025-04-30\n\n0001557376\n\nzeox:LeaseAgreementMember\n\n2025-04-01\n2025-04-30\n\n0001557376\n\nzeox:LeaseAgreementMember\n\n2025-06-30\n\n0001557376\n\nzeox:LeaseAgreementMember\n\n2025-06-01\n2025-06-30\n\n0001557376\n\nzeox:ManagementServicesOrganizationMember\n\n2026-02-01\n2026-04-30\n\n0001557376\n\nzeox:ManagementServicesOrganizationMember\n\n2025-02-01\n2025-04-30\n\n0001557376\n\nzeox:ManagementServicesOrganizationMember\n\n2025-11-01\n2026-04-30\n\n0001557376\n\nzeox:ManagementServicesOrganizationMember\n\n2024-11-01\n2025-04-30\n\n0001557376\n\nzeox:SalesAgreementMember\n\n2025-02-01\n2025-04-30\n\n0001557376\n\nzeox:SalesAgreementMember\n\n2024-11-01\n2025-04-30\n\n0001557376\n\nzeox:ConvertiblePromissoryNotesMember\n\n2025-11-01\n2026-04-30\n\n0001557376\n\nzeox:ConvertiblePromissoryNotesMember\n\n2026-04-30\n\n0001557376\n\nzeox:ConvertiblePromissoryNotesMember\n\n2026-02-01\n2026-04-30\n\n0001557376\n\nzeox:ConvertiblePromissoryNotesMember\n\n2025-02-01\n2025-04-30\n\n0001557376\n\nzeox:ConvertiblePromissoryNotesMember\n\n2024-11-01\n2025-04-30\n\n0001557376\n\nzeox:N2021PlanMember\n\n2021-09-01\n2021-09-30\n\n0001557376\n\nzeox:N2021PlanMember\n\n2023-06-01\n2023-06-06\n\n0001557376\n\nzeox:N2021PlanMember\n\n2026-06-01\n2026-06-10\n\n0001557376\n\nzeox:N2021PlanMember\n\n2026-04-30\n\n0001557376\n\nzeox:SubscriptionAgreementMember\nus-gaap:InvestorMember\n\n2025-07-01\n2025-07-25\n\n0001557376\n\nzeox:SubscriptionAgreementMember\n\n2024-11-01\n2025-10-31\n\n0001557376\n\nzeox:SubscriptionAgreementMember\n\n2025-10-28\n2025-11-02\n\n0001557376\n\nzeox:SubscriptionAgreementMember\n\n2026-02-01\n2026-02-10\n\n0001557376\n\nzeox:SubscriptionAgreementMember\n\n2025-11-01\n2026-04-30\n\n0001557376\n\nzeox:EightInvestorsMember\n\n2025-11-01\n2026-04-30\n\n0001557376\n\nzeox:ConsultingAgreementMember\nzeox:ConsultantMember\n\n2025-11-30\n2025-12-01\n\n0001557376\n\nzeox:ConsultingAgreementMember\nzeox:ConsultantMember\n\n2025-12-01\n\n0001557376\n\nzeox:ConsultingAgreementMember\nzeox:ConsultantMember\n\n2026-02-01\n2026-04-30\n\n0001557376\n\nzeox:ConsultingAgreementMember\nzeox:ConsultantMember\n\n2025-11-01\n2026-04-30\n\n0001557376\n\nzeox:N2021IncentiveStockPlanMember\nzeox:EmployeeMember\n\n2025-12-02\n2025-12-23\n\n0001557376\n\nzeox:N2021IncentiveStockPlanMember\nzeox:EmployeeMember\n\n2025-12-23\n\n0001557376\n\nzeox:N2021IncentiveStockPlanMember\nzeox:EmployeeMember\n\n2026-02-01\n2026-04-30\n\n0001557376\n\nzeox:N2021IncentiveStockPlanMember\nzeox:EmployeeMember\n\n2025-11-01\n2026-04-30\n\n0001557376\n\nzeox:N2021PlanMember\nsrt:ChiefExecutiveOfficerMember\nzeox:IanBothwellMember\n\n2026-01-01\n2026-01-14\n\n0001557376\n\nzeox:N2021PlanMember\nzeox:ChiefMedicalOfficerMember\nzeox:DrGeorgeShapiroMember\n\n2026-01-01\n2026-01-14\n\n0001557376\n\nzeox:N2021PlanMember\nzeox:GreytVenturesLLCMember\n\n2026-01-01\n2026-01-14\n\n0001557376\n\nzeox:N2021PlanMember\n\n2026-01-01\n2026-01-14\n\n0001557376\n\nzeox:N2021PlanMember\n\n2026-01-14\n\n0001557376\n\nzeox:N2021PlanMember\n\n2026-02-01\n2026-04-30\n\n0001557376\n\nzeox:N2021PlanMember\n\n2025-11-01\n2026-04-30\n\n0001557376\n\nzeox:EmploymentAgreementMember\nzeox:N2021PlanMember\nzeox:DrKisidayMember\n\n2026-01-01\n2026-01-14\n\n0001557376\n\nzeox:EmploymentAgreementMember\nzeox:N2021PlanMember\nzeox:DrKisidayMember\n\n2026-01-14\n\n0001557376\n\nzeox:ConsultantMember\n\n2026-02-01\n2026-04-30\n\n0001557376\n\nsrt:MinimumMember\nzeox:ConsultantMember\n\n2026-04-30\n\n0001557376\n\nzeox:ConsultantMember\nsrt:MaximumMember\n\n2026-04-30\n\n0001557376\n\nzeox:ConsultantMember\n\n2025-11-01\n2026-04-30\n\n0001557376\n\nzeox:RestrictedStockAwardsMember\n\n2026-04-30\n\n0001557376\n\nzeox:UnvestedRestrictedStockMember\n\n2025-10-31\n\n0001557376\n\nzeox:UnvestedRestrictedStockMember\n\n2025-11-01\n2026-04-30\n\n0001557376\n\nzeox:UnvestedRestrictedStockMember\n\n2026-04-30\n\n0001557376\n\nus-gaap:StockOptionMember\n\n2025-10-31\n\n0001557376\n\nus-gaap:StockOptionMember\n\n2025-11-01\n2026-04-30\n\n0001557376\n\nus-gaap:StockOptionMember\n\n2026-04-30\n\n0001557376\n\nzeox:EmployeesMember\n\n2025-11-01\n2026-04-30\n\n0001557376\n\nus-gaap:StockOptionMember\n\n2026-02-01\n2026-04-30\n\n0001557376\n\nus-gaap:StockOptionMember\n\n2025-02-01\n2025-04-30\n\n0001557376\n\nus-gaap:StockOptionMember\n\n2024-11-01\n2025-04-30\n\n0001557376\n\nus-gaap:WarrantMember\n\n2026-02-01\n2026-04-30\n\n0001557376\n\nus-gaap:WarrantMember\n\n2025-02-01\n2025-04-30\n\n0001557376\n\nus-gaap:WarrantMember\n\n2025-11-01\n2026-04-30\n\n0001557376\n\nus-gaap:WarrantMember\n\n2024-11-01\n2025-04-30\n\n0001557376\n\nus-gaap:WarrantMember\n\n2026-04-30\n\n0001557376\n\nus-gaap:WarrantMember\n\n2025-10-31\n\n0001557376\n\nzeox:EmploymentAgreementMember\nzeox:N2021IncentiveStockPlanMember\nzeox:DrKisidayMember\n\n2026-01-01\n2026-01-23\n\n0001557376\n\nzeox:SupplyAgreementMember\n\n2026-04-30\n\n0001557376\n\nzeox:SupplyAgreementMember\n\n2025-10-31\n\n0001557376\n\nzeox:HowardGolubMember\n\n2024-11-01\n2024-11-19\n\n0001557376\n\nzeox:TwoInvestorsMember\nus-gaap:SubsequentEventMember\n\n2026-05-01\n2026-06-15\n\niso4217:USD\n\nxbrli:shares\n\niso4217:USD\n\nxbrli:shares\n\nxbrli:pure\n\nzeox:Integer\n\n \n\n \n\n \n\n**UNITED STATES**\n\n**SECURITIES AND EXCHANGE COMMISSION**\n\n**WASHINGTON, DC 20549**\n\n \n\n**FORM 10-Q**\n\n \n\n☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934\n\n \n\nFor the quarterly period ended **April 30, 2026**\n\n \n\nOR\n\n \n\n☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934\n\n \n\nFor the transition period from ____________ to ____________\n\n \n\nCommission file number: **000-55008**\n\n** **\n\n**Zeo ScientifiX, Inc.**\n\n(Exact Name of Registrant as Specified in Its Charter)\n\n \n\n**Nevada**\n** **\n**47-4180540**\n\n(State or Other Jurisdiction of\nIncorporation or Organization)\n \n(I.R.S. Employer\nIdentification No.)\n\n \n \n \n\n**3321 College Avenue, Suite 246**\n\n**Davie, FL**\n\n** **\n**33314**\n\n(Address of Principal Executive Offices)\n \n(Zip Code)\n\n \n\nRegistrant’s Telephone Number, Including Area Code: (**888) 963-7881**\n\n \n\n**Securities registered pursuant to Section 12(b) of the Act:**\n\n \n\n**Title of each class**\n \n**Trading Symbol(s)**\n \n**Name of each exchange on which registered**\n\nNone\n \nN/A\n \nN/A\n\n \n\n**Securities registered pursuant to Section 12(g) of the Act:**Common Stock, $0.001 par value\n\n \n\nIndicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒   No ☐\n\n \n\nIndicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the Registrant was required to submit such files.) Yes ☒   No ☐\n\n \n\nIndicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of “accelerated filer”, “large accelerated filer,” “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act.\n\n \n\nLarge Accelerated Filer\n☐\nAccelerated Filer\n☐\n\nNon-Accelerated Filer\n☒\nSmaller reporting company\n☒\n\n \n \nEmerging growth company\n☐\n\n \n\nIf an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐\n\n \n\nIndicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐   No ☒\n\n \n\nAs of June 12, 2026, there were 7,837,441 shares of common stock, $0.001 par value per share, issued and outstanding.\n\n \n\n \n\n \n\n \n\n \n\n \n\n**ZEO SCIENTIFIX, INC.**\n\n \n\n**TABLE OF CONTENTS**\n\n \n\n \n \n \n \n**PAGE NO.**\n\n**PART I**\n \n[**FINANCIAL INFORMATION**](#a_001)\n \n \n\n \n \n \n \n \n\n[Item 1.](#a_002)\n \n[Condensed Unaudited Financial Statements](#a_002)\n \n1\n\n \n \n \n \n \n\n[Item 2.](#a_003)\n \n[Management’s Discussion and Analysis of Financial Condition and Results of Operations.](#a_003)\n \n22\n\n \n \n \n \n \n\n[Item 3.](#a_004)\n \n[Quantitative and Qualitative Disclosures About Market Risk.](#a_004)\n \n29\n\n \n \n \n \n \n\n[Item 4.](#a_005)\n \n[Controls and Procedures.](#a_005)\n \n29\n\n \n \n \n \n \n\n**PART II**\n \n[**OTHER INFORMATION**](#a_006)\n \n** **\n\n \n \n \n \n \n\n[Item 1.](#a_007)\n \n[Legal Proceedings.](#a_007)\n \n30\n\n \n \n \n \n \n\n[Item 1A.](#a_008)\n \n[Risk Factors.](#a_008)\n \n31\n\n \n \n \n \n \n\n[Item 2.](#a_009)\n \n[Unregistered Sales of Equity Securities and Use of Proceeds.](#a_009)\n \n31\n\n \n \n \n \n \n\n[Item 3.](#a_010)\n \n[Defaults Upon Senior Securities.](#a_010)\n \n31\n\n \n \n \n \n \n\n[Item 4.](#a_011)\n \n[Mine Safety Disclosures.](#a_011)\n \n31\n\n \n \n \n \n \n\n[Item 5.](#a_012)\n \n[Other Information.](#a_012)\n \n31\n\n \n \n \n \n \n\n[Item 6.](#a_013)\n \n[Exhibits.](#a_013)\n \n32\n\n \n \n \n \n \n\n[Signatures](#a_014)\n \n33\n\n \n\ni\n\n \n\n \n\nUnless stated otherwise, the words “we,” “us,” “our,” the “Company” or “ZEO” in this Quarterly Report on Form 10-Q (this “Report”) refer to Zeo ScientifiX, Inc., a Nevada corporation, and its subsidiaries.\n\n \n\n**Cautionary Note Regarding Forward- Looking Statements**\n\n \n\nThe statements contained in this Report that are not historical facts are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 (the “Securities Act”) and Section 21E of the Securities Exchange Act of 1934 (the “Exchange Act”). These forward-looking statements are identified as any statement that does not relate strictly to historical or current facts. Statements using words such as “may,” “could,” “should,” “expect,” “plan,” “project,” “strategy,” “forecast,” “intend,” “anticipate,” “believe,” “estimate,” “predict,” “potential,” “pursue,” “target,” “continue,” or similar expressions help identify forward-looking statements.\n\n \n\nThe forward-looking statements contained in this Report are largely based on our expectations, which reflect estimates and assumptions made by our management. These estimates and assumptions reflect our best judgment based on currently known market conditions and other factors. Although we believe such estimates and assumptions to be reasonable, they are inherently uncertain and involve a number of risks and uncertainties that are beyond our control. In addition, management’s assumptions about future events may prove to be inaccurate. Management cautions all readers that the forward-looking statements contained in this Report are not guarantees of future performance, and management cannot assure any reader that such statements will be realized or the forward-looking events and circumstances will in fact occur. The Company’s actual results may differ materially from those anticipated, estimated, projected or expected by management.\n\n \n\nAll forward-looking statements speak only as of the date of this Report. We do not intend to publicly update or revise any forward-looking statements as a result of new information, future events or otherwise.\n\n \n\nii\n\n \n\n \n\n**Part I – FINANCIAL INFORMATION**"}